Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa
First subject dosed in Phase I study to evaluate safety and tolerability of…
COVID-19 Pandemic Triggers Upsurge in MBL Infections
New research has discovered that the ongoing COVID-19 pandemic has triggered a…
Infex Therapeutics to begin clinical development of anti-virulence therapy for Pseudomonas aeruginosa (Pa) in non-cystic fibrosis bronchiectasis patients
MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022…
Infex scientists achieve breakthrough to overcome critical priority drug resistant infections
Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech…
Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains
Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech…
Infex Therapeutics sharpens Covid focus with new CRUK Newcastle partnership
Alderley Park, Cheshire - Infex Therapeutics is pressing ahead with a major…
Deals agreed as Infex’s resistance bypass drug program heads for clinic
Alderley Park, Cheshire Infex Therapeutics has appointed Pharmaron to help…
Infex focuses on pandemic preparedness with Covid patent
Infex Therapeutics has filed for a UK patent for a novel therapy designed to…
Infex Therapeutics and LifeArc in Collaboration to Defeat Superbugs
Infex Therapeutics has combined forces with medical research charity, LifeArc,…